What's Happening?
Calyxo, Inc. has raised $40 million in a Series F financing round to support the expansion of its CVAC System, a minimally invasive kidney stone removal technology. The funding, led by Ally Bridge Group and Janus Henderson Investors, will be used to enhance
commercial infrastructure, generate clinical evidence, and drive innovation. The CVAC System has treated over 40,000 patients, offering a more efficient and effective solution for kidney stone clearance through continuous aspiration of stone fragments.
Why It's Important?
The investment in Calyxo highlights the growing demand for advanced medical technologies that improve patient outcomes and reduce healthcare costs. Kidney stone disease affects a significant portion of the population, and the CVAC System's ability to achieve complete stone clearance represents a major advancement in treatment. The funding will enable Calyxo to expand its market presence and continue developing its technology, potentially setting a new standard of care in kidney stone management.
